Enovis (ENOV) | Stock Overview & Key Data
Enovis Performance Comparison
Stock Range
Today's Range
Low: $25.70
High: $26.62
on August 1, 2025
52 Week Range
Low: $25.70
High: $49.83
on August 1, 2025
on November 6, 2024
All-Time High: $129.72 on June 9, 2014
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$1.5B
EPS
-14.64
P/E Ratio (TTM)
-1.72
Forward P/E
8.15
P/B Ratio
0.56
PEG Ratio
8.15
Div. Yield
N/A
ROE
-27.35%
Beta
1.811
Debt to Equity
55.68
Financial Highlights
Profitability
Gross Margin
59.45%
Operating Margin
-5.50%
Profit Margin
-37.65%
Returns and Earnings
Return on Assets (TTM)
0.49%
Return on Equity (TTM)
-27.35%
EBITDA
$191.3M
Net Income (TTM)
$-811.9M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$38.48
Quarterly Revenue Growth (YoY)
8.20%
Quarterly Earnings Growth (YoY)
8.25%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Enovis ENOV | 1.53B Small-cap | -6.54% | -22.05% | -25.61% | -43.14% | -41.90% | -43.30% | -55.94% | -55.10% |
| Abbott Laboratories ABT | 221.54B Mega-cap | 0.59% | -6.58% | -2.74% | -0.90% | 12.21% | 14.36% | 16.51% | 25.74% |
| Boston Scientific BSX | 155.95B Large-cap | -0.69% | 0.60% | 2.15% | 2.27% | 17.93% | 41.49% | 157.47% | 170.49% |
| UFP Technologies UFPT | 1.75B Small-cap | -6.35% | -10.22% | 6.71% | -16.34% | -7.98% | -28.36% | 154.14% | 406.53% |
| Conmed CNMD | 1.62B Small-cap | 2.63% | -3.29% | -8.57% | -26.57% | -22.36% | -23.85% | -46.10% | -38.46% |
| QuidelOrtho QDEL | 1.54B Small-cap | -16.72% | -23.43% | -18.19% | -46.37% | -49.36% | -45.70% | -75.26% | -91.64% |
Ownership & Short Interest
Insider Ownership
1.54%
Institutional Ownership
106.92%
Shares Short
7M
Short Ratio
4.68
Short % of Shares Outstanding
19.56%
Average 10-Day Volume
1M
Average 90-Day Volume
2M
Enovis Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Enovis would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is ENOV's 52-week high and low?
- In the last 52 weeks, Enovis reached a high of $49.83 (on November 6, 2024) and a low of $25.70 (on August 1, 2025).
- What is the market cap and P/E ratio for ENOV?
- Curious about Enovis's size and valuation? Its market capitalization stands at 1.53B. When it comes to valuation, the P/E ratio (trailing twelve months) is -1.72, and the forward P/E (looking ahead) is 8.15.
- Does ENOV pay dividends? If so, what's the yield?
- As for dividends, Enovis isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Enovis's main competitors or similar companies to consider before investing?
When looking at Enovis, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT221.54B Healthcare Medical Devices 14.36% 16.51% Boston Scientific
BSX155.95B Healthcare Medical Devices 41.49% 157.47% UFP Technologies
UFPT1.75B Healthcare Medical Devices -28.36% 154.14% Conmed
CNMD1.62B Healthcare Medical Devices -23.85% -46.10% QuidelOrtho
QDEL1.54B Healthcare Medical Devices -45.70% -75.26% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Enovis Corporation? (e.g., ROE, Debt/Equity)
- To get a sense of Enovis's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -27.35%, the Debt to Equity ratio from the most recent quarter is 55.68, and its Gross Profit Margin stands at 59.45%.
- What is the recent revenue and earnings growth for ENOV?
- Looking at Enovis's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.20%, and quarterly earnings saw a YoY growth of 8.25%.
- How much of ENOV stock is held by insiders and institutions?
- Wondering who owns Enovis stock? Company insiders (like executives and directors) hold about 1.54% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 106.92%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.